Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ficerafusp alfa plus pembrolizumab versus placebo plus pembrolizumab in first-line PD-L1-positive recurrent or metastatic head and neck squamous cell carcinoma
MOH_2026-03-29_015745Phase 3Recruiting
- Sponsor
- Bicara Therapeutics
- Start
- Mar 2026
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of ficerafusp alfa and pembrolizumab in head and neck squamous cell carcinoma (HNSCC), sponsored by Bicara Therapeutics. Primary endpoint: Optimal biologic dose selection. Started Mar 2026; status: recruiting.
02
Drugs
ficerafusp alfapembrolizumab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on MOH_2026-03-29_015745.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2026-03-29_015745.